Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
- Tuesday, July 26, 2022, 7:14
- Environment
- Add a comment
Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious…
About the Author
adminasapcorp has written 39026 stories on this site.